| Name | Title | Contact Details |
|---|
With iCAD`s technology, cancer has finally met its match. As a global medical technology leader providing innovative cancer detection and therapy solutions, our technologies empower clinicians worldwide with an arsenal of tools to detect cancer and stop it in its tracks – streamlining workflow, improving accuracy, and personalizing results like never before. The ProFound AI Breast Health Suite is the first, best, and only complete, triple-threat solution that combines cancer detection, density assessment, and risk evaluation – all designed to accelerate discovery and improve outcomes. Our leading-edge cancer detection solution, ProFound AI®, is clinically proven to find cancers earlier and with greater accuracy, while slashing reading time for radiologists by more than half. PowerLook® Density Assessment simplifies and standardizes breast density reporting and stratification, offering consistent, accurate and reliable breast density categorization. And the latest addition to our Breast AI Suite, ProFound AI® Risk, is the world`s first clinical decision support tool that provides an accurate short-term breast cancer risk estimation that is truly personalized for each woman, based only on her mammogram. Our Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is transforming the cancer treatment experience by empowering physicians to precisely and effectively target tumors anywhere in the body, anywhere in the world. Using the world`s smallest X-ray source, clinicians can precisely destroy disease while preserving healthy tissue, leaving cancer nowhere to hide.
Capistrano Lab Inc is a San Clemente, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Prestige Medical is a Northridge, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Trice Medical was founded to fundamentally improve orthopedic diagnostics. Trice has pioneered fully integrated camera-enabled technologies that provide a clinical solution that is optimized for the physicians office. Our mission is to provide more immediate and definitive patient care, eliminating the false reads associated with current indirect modalities and significantly reduce the overall cost to the healthcare system.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.